Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 04/08/2024 at 07:00, 7 months 13 days ago

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals presented data from study 014/015 and evenamide clinical development outlook at SIRS 2024 Congress, showcasing potential for new TRS treatment options

Clinical Development Newron Pharmaceuticals Evenamide Study 014/015 Schizophrenia International Research Society
BRIEF

published on 03/19/2024 at 07:05, 8 months 2 days ago

Newron Pharmaceuticals S.p.A. Announces 2023 Financial Results and Provides Outlook for 2024

2024 Outlook Financial Results 2023 Newron Pharmaceuticals Evenamide Development Xadago Safinamide
BRIEF

published on 03/19/2024 at 07:05, 8 months 2 days ago

Newron Pharmaceuticals SpA annonce ses résultats financiers pour 2023 et fournit des perspectives pour 2024

Perspectives 2024 Résultats Financiers 2023 Produits Pharmaceutiques Newron Xadago Safinamide Développement D'Evenamide
PRESS RELEASE

published on 03/19/2024 at 07:00, 8 months 2 days ago

Newron presents 2023 financial results and provides 2024 outlook
Newron Pharmaceuticals S.p.A. presents 2023 financial results and 2024 outlook, including advancements in schizophrenia treatment and strategic partnerships

Financial Results 2024 Outlook Partnerships Newron Pharmaceuticals Schizophrenia Treatment
BRIEF

published on 03/15/2024 at 07:05, 8 months 6 days ago

Newron Pharmaceuticals SpA annonce un accord de remboursement modifié avec la Banque européenne d'investissement

Produits Pharmaceutiques Newron Evenamide Banque Européenne D'investissement Accord De Financement Traitements Du SNC
BRIEF

published on 03/15/2024 at 07:05, 8 months 6 days ago

Newron Pharmaceuticals S.p.A. Announces Amended Repayment Agreement with European Investment Bank

European Investment Bank Newron Pharmaceuticals Financing Agreement Evenamide CNS Treatments
PRESS RELEASE

published on 03/15/2024 at 07:00, 8 months 6 days ago

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A. agrees with EIB to extend repayment dates of 2018 financing agreement tranches after pipeline milestones

European Investment Bank Financing Agreement Evenamide Newron Pharmaceuticals S.p.A. Loan Repayment Dates
BRIEF

published on 03/14/2024 at 18:37, 8 months 6 days ago

Newron Pharmaceuticals obtient jusqu'à 15 millions d'euros de financement grâce à l'émission de nouvelles actions

Émission D'actions Produits Biopharmaceutiques Accord D'investissement Produits Pharmaceutiques Newron Thérapies Du SNC
BRIEF

published on 03/14/2024 at 18:37, 8 months 6 days ago

Newron Pharmaceuticals Secures Up to EUR 15 Million in Funding Through New Share Issuance

Share Issuance Biopharmaceuticals Investment Agreement Newron Pharmaceuticals CNS Therapies
PRESS RELEASE

published on 03/14/2024 at 18:32, 8 months 6 days ago

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A. enters a subscription agreement for up to 2.05 million new shares, aiming to raise EUR 15.0 million. The investment supports CNS therapies development

Subscription Agreement Newron Pharmaceuticals Newly Issued Shares EUR 15.0 Million CNS Therapies Development

Published on 11/21/2024 at 16:30, 13 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 42 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 43 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 43 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 43 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 43 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 1 hour 1 minute ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 20 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 21 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 9 hours 45 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 45 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 45 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 35 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 23 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News